Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Work In Process (2023 - 2025)

Tg Therapeutics (TGTX) has 3 years of Work In Process data on record, last reported at $121.8 million in Q3 2025.

  • For Q3 2025, Work In Process rose 62.47% year-over-year to $121.8 million; the TTM value through Sep 2025 reached $121.8 million, up 62.47%, while the annual FY2024 figure was $68.4 million, 118.84% up from the prior year.
  • Work In Process reached $121.8 million in Q3 2025 per TGTX's latest filing, down from $129.2 million in the prior quarter.
  • Across five years, Work In Process topped out at $142.9 million in Q1 2025 and bottomed at $27.1 million in Q1 2023.
  • Average Work In Process over 3 years is $73.5 million, with a median of $74.1 million recorded in 2024.
  • Peak YoY movement for Work In Process: skyrocketed 172.99% in 2024, then surged 62.47% in 2025.
  • A 3-year view of Work In Process shows it stood at $31.2 million in 2023, then soared by 118.84% to $68.4 million in 2024, then skyrocketed by 78.16% to $121.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $121.8 million in Q3 2025, $129.2 million in Q2 2025, and $142.9 million in Q1 2025.